PLCG1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL415590	0.54	3/20
SCHEMBL415569	0.51	3/20
SCHEMBL723264	0.51	3/20
9,10-Phenanthrenequinone (SCHEMBL43050)	1.00	2/20
SCHEMBL760965	0.91	2/20
SCHEMBL40960	0.87	2/20
SCHEMBL43327	0.63	2/20
SCHEMBL939283	0.63	2/20
SCHEMBL547774	0.63	2/20
SCHEMBL547775	0.63	2/20
SCHEMBL745377	0.59	2/20
SCHEMBL347152	0.57	2/20
SCHEMBL64761	0.56	2/20
SCHEMBL236156	0.55	2/20
SCHEMBL482129	0.55	2/20
SCHEMBL857051	0.54	2/20
SCHEMBL571761	0.52	2/20
SCHEMBL18844	0.52	2/20
SCHEMBL79475	0.52	2/20
SCHEMBL88058	0.52	2/20

Clinical trials — most relevant to PLCG1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib	PHASE1	ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A	EARLY_PHASE1	COMPLETED
Molecular Markers of Human Sperm Function	nan	WITHDRAWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Clinical Characteristics of Primary Liver Cancer	nan	UNKNOWN
Plaque Calcium Characterization and Ruptured Plaques	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Candida Associated Cytokines in Oral Leukoplakia	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Liver Cancer Prognosis Investigation Study	nan	NOT_YET_RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential	nan	NOT_YET_RECRUITING
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations	nan	WITHDRAWN
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PLCG1 binder may also engage these)

Protein	Name	Similarity
P10686	—	1.000	P10686 →
Q62077	—	1.000	Q62077 →
P08487	—	1.000	P08487 →
Q8CIH5	—	1.000	Q8CIH5 →
P24135	—	1.000	P24135 →
Q22070	—	1.000	Q22070 →
PLCG2	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2	1.000	landscape →
Q9H1H9	—	0.996	Q9H1H9 →
Q9NPF8	—	0.995	Q9NPF8 →
B4NBB0	—	0.993	B4NBB0 →
Q9JK15	—	0.993	Q9JK15 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.993	landscape →
Q03603	—	0.993	Q03603 →
O95759	—	0.993	O95759 →
P25799	—	0.993	P25799 →
P70600	—	0.992	P70600 →
B0R0W9	—	0.992	B0R0W9 →
KDM5B	Lysine-specific demethylase 5B	0.992	landscape →
INPP5B	Type II inositol 1,4,5-trisphosphate 5-phosphatase	0.992	landscape →
Q9TTH8	—	0.992	Q9TTH8 →
O12990	—	0.992	O12990 →
KAT8	Histone acetyltransferase KAT8	0.992	landscape →
Q9EQW7	—	0.991	Q9EQW7 →
A2CEA7	—	0.991	A2CEA7 →
Q12756	—	0.991	Q12756 →
Q60629	—	0.991	Q60629 →
Q5BJS0	—	0.991	Q5BJS0 →
B4LX81	—	0.991	B4LX81 →
B3M383	—	0.991	B3M383 →
P54936	—	0.991	P54936 →